Table 1 FDA-approved targeting nanodrugs for HER2-positive breast cancer
From: Nanotechnology approaches to addressing HER2-positive breast cancer
Targeting drug specific to HER2 | Mechanism of action | Reference |
|---|---|---|
Trastuzumab (Herceptin) | Monoclonal antibody that binds to the extracellular domain (ECD) of the HER2/neu receptor | Targeted therapy (2019) |
Pertuzumab (Perjeta) | Inhibits dimerization of HER2 receptors by binding to special epitope of the extracellular domain (ECD) | PERJETA and HER2+ breast cancer (2019) |
Ado-trastuzumab emtansine (Kadcyla or TDM-1) | Targets HER2 receptors with trastuzumab and delivers the inhibitor emtancine to arrest and kill cancer cells | Chemocare.com (2019) |
Lapatinib | Receptor tyrosine kinase inhibitor in the ICD | Targeted therapy (2019) |
Neritinib | Receptor tyrosine kinase inhibitor in the ICD | U.S. National Library of Medicine (2019) |
Bevacizumab | VEGF inhibitor; reduces the cancers blood supply | Targeted therapy, 2019 |
Fam-trastuzumab-deruxtecan | Humanized IgG1 monoclonal antibody, which has the same amino acid sequence as trastuzumab (and targets HER2. The deruxtecan component is a topoisomerase inhibitor | Fam-Trastuzumab Deruxtecan (2020) |
Tucatinib | Selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells | Tucatinib (2020) |